BioSig Technologies terminated its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, with approximately $29.9 million in shares of Common Stock remaining available for sale under the agreement.
AI Assistant
BIOSIG TECHNOLOGIES INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.